APPG calls for long term conditions to be part of new pharmacy contract

APPG calls for long term conditions to be part of new pharmacy contract

July 16 2018 Community pharmacy’s involvement in managing long term conditions should be...

NICE updates guideline on rheumatoid arthritis

NICE updates guideline on rheumatoid arthritis

July 13 2018 NICE has issued a new version of its guideline on the management of rheumatoid...

RPS seeks views on draft guidance around polypharmacy

RPS seeks views on draft guidance around polypharmacy

July 13 2018 The Royal Pharmaceutical Society is seeking comments to hone draft guidance on...

NMS sees 4.5% referral rate to GP for newly prescribed antihypertensives

NMS sees 4.5% referral rate to GP for newly prescribed antihypertensives

July 11 2018 New Medicines Service data indicates community pharmacists manage 19 out of 20...

PDA: ‘Pharmacy technicians don’t want to be responsible for supervising pharmacies’

PDA: ‘Pharmacy technicians don’t want to be responsible for supervising pharmacies’

July 10 2018 Pharmacy technicians have indicated concerns about the possibility that their role...

  • APPG calls for long term conditions to be part of new pharmacy contract

    APPG calls for long term conditions to be part of new pharmacy contract

    Monday, 16 July 2018 15:44
  • NICE updates guideline on rheumatoid arthritis

    NICE updates guideline on rheumatoid arthritis

    Friday, 13 July 2018 12:51
  • RPS seeks views on draft guidance around polypharmacy

    RPS seeks views on draft guidance around polypharmacy

    Friday, 13 July 2018 12:47
  • NMS sees 4.5% referral rate to GP for newly prescribed antihypertensives

    NMS sees 4.5% referral rate to GP for newly prescribed antihypertensives

    Wednesday, 11 July 2018 13:02
  • PDA: ‘Pharmacy technicians don’t want to be responsible for supervising pharmacies’

    PDA: ‘Pharmacy technicians don’t want to be responsible for supervising pharmacies’

    Tuesday, 10 July 2018 09:23

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageJanuary 10 2018

The medicines regulator has highlighted the different strengths of co-dydramol in its latest Drug Safety Update. 

For many years co-dydramol has been available at a fixed ratio of 1:50, combining dihydrocodeine 10mg and paracetamol 500mg. However, the MHRA’s latest DSU is advising that new strengths containing greater amounts of dihydrocodeine – co-dydramol 20/500 mg and co-dydramol 30/500 mg tablets – are becoming available.

Health professionals should take care to ensure the intended strength is clearly prescribed and the correct strength is dispensed, says the MHRA. If the prescribed strength is unclear, the person dispensing should contact the prescriber for clarification. It is also asking that health professionals “report suspected adverse drug reactions with opioids, including any harm from medication error, via the Yellow Card Scheme.”

The January 6 DSU newsletter also asks health professionals to ask if a patient has been using herbal medicines when reporting any suspected adverse drug reaction. If herbal medicines or traditional Chinese medicines have been used, this information should be included on the Yellow Card scheme report.

Ideally, information about a herbal product should include the brand name, the list of ingredients, a copy of the package labelling if available, and any manufacturer details. Patients should also be advised to check for the Traditional Herbal Registration Certification Mark.

Another medicine included in the DSU newsletter is daclizumab (daclizumab beta), which is “now restricted to adults with relapsing multiple sclerosis who have had an inadequate response to at least two other disease-modifying therapies (DMTs) and for whom other DMTs are contraindicated or unsuitable.”

The MHRA is advising that patients with pre-existing hepatic disease or hepatic impairment should not use daclizumab. Caution should also be taken in prescribing daclizumab “in patients receiving other medication that may be hepatotoxic, including over-the-counter products and herbal medicines.”

Links:
MHRA Drug Safety Update: monthly PDF newsletters        
MHRA Drug Safety Update: monthly PDF newsletter. January 6 2018. 11;6.                 
Co-dydramol DSU             
Herbal medicines DSU    
Daclizumab DSU                

Practice News

July 18 2018 Community pharmacists should be among those health professionals who are alerted to a patient being included on the Palliative Care Register, Welsh Assembly Members have recommended.
July 11 2018 New Medicines Service data indicates community pharmacists manage 19 out of 20 hypertensive patients without the need to refer a patient back to the GP. Analysis of 131,419 patient...